Literature DB >> 21606177

Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.

Nancy N Jong1, Takeo Nakanishi, Johnson J Liu, Ikumi Tamai, Mark J McKeage.   

Abstract

The organic cation/carnitine transporters OCTN1 and OCTN2 are related to other organic cation transporters (OCT1, OCT2, and OCT3) known for transporting oxaliplatin, an anticancer drug with dose-limiting neurotoxicity. In this study, we sought to determine whether OCTN1 and OCTN2 also transported oxaliplatin and to characterize their functional expression and contributions to its neuronal accumulation and neurotoxicity in dorsal root ganglion (DRG) neurons relative to those of OCTs. [(14)C]Oxaliplatin uptake, platinum accumulation, and cytotoxicity were determined in OCTN-overexpressing human embryonic kidney (HEK) 293 cells and primary cultures of rat DRG neurons. Levels of mRNA and functional activities of rat (r)Octns and rOcts in rat DRG tissue and primary cultures were characterized using reverse transcription-polymerase chain reaction and uptake of model OCT/OCTN substrates, including [(3)H]1-methyl-4-phenylpyridinium (MPP(+)) (OCT1-3), [(14)C]tetraethylammonium bromide (TEA(+)) (OCT1-3 and OCTN1/2), [(3)H]ergothioneine (OCTN1), and [(3)H]l-carnitine (OCTN2). HEK293 cells overexpressing rOctn1, rOctn2, human OCTN1, and human OCTN2 showed increased uptake and cytotoxicity of oxaliplatin compared with mock-transfected HEK293 controls; in addition, both uptake and cytotoxicity were inhibited by ergothioneine and L-carnitine. The uptake of ergothioneine mediated by OCTN1 and of L-carnitine mediated by OCTN2 was decreased during oxaliplatin exposure. rOctn1 and rOctn2 mRNA was readily detected in rat DRG tissue, and they were functionally active in cultured rat DRG neurons, more so than rOct1, rOct2, or rOct3. DRG neuronal accumulation of [(14)C]oxaliplatin and platinum during oxaliplatin exposure depended on time, concentration, temperature, and sodium and was inhibited by ergothioneine and to a lesser extent by L-carnitine but not by MPP(+). Loss of DRG neuronal viability during oxaliplatin exposure was inhibited by ergothioneine but not by L-carnitine or MPP(+). OCTN1 and OCTN2 both transport oxaliplatin and are functionally expressed by DRG neurons. OCTN1-mediated transport of oxaliplatin appears to contribute to its neuronal accumulation and treatment-limiting neurotoxicity more so than OCTN2 or OCTs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606177     DOI: 10.1124/jpet.111.181297

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  52 in total

Review 1.  Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.

Authors:  Marco Sisignano; Ralf Baron; Klaus Scholich; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2014-11-04       Impact factor: 42.937

Review 2.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

Review 3.  Emerging trends in understanding chemotherapy-induced peripheral neuropathy.

Authors:  Jérémy Ferrier; Vanessa Pereira; Jérome Busserolles; Nicolas Authier; David Balayssac
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 4.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

5.  Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues.

Authors:  Rajendra S Kadam; Sunil K Vooturi; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2012-11-20       Impact factor: 3.922

6.  Evaluation of Cisplatin Neurotoxicity in Cultured Rat Dorsal Root Ganglia via Cytosolic Calcium Accumulation.

Authors:  Kevser Erol; Semra Yiğitaslan; Çiğdem Ünel; Bilgin Kaygısız; Engin Yıldırım
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

Review 7.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 8.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12

9.  Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.

Authors:  Justin C Jagodinsky; Agnieszka Sulima; Yiqi Cao; Joanna E Poprawski; Burchelle N Blackman; John R Lloyd; Rolf E Swenson; Michael M Gottesman; Matthew D Hall
Journal:  J Biol Inorg Chem       Date:  2015-09-01       Impact factor: 3.358

10.  Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.

Authors:  Jason A Sprowl; Giuliano Ciarimboli; Cynthia S Lancaster; Hugh Giovinazzo; Alice A Gibson; Guoqing Du; Laura J Janke; Guido Cavaletti; Anthony F Shields; Alex Sparreboom
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.